Table 1.
Potencies, expressed as IC50 concentrations for pyriplatin, cisplatin, and oxaliplatin, on cancer cell proliferation in the 10-cell line panel after a 24-h incubation period.
| Cell Line | Cancer Type | IC50 |
||
|---|---|---|---|---|
| Pyriplatin | Cisplatin | Oxaliplatin | ||
| HOP-92 | Non-Small Cell Lung | 171 ± 56 μM | 3.55 ± 3.2 μM | 2.70 ± 0.60 μM |
| HOP-62 | Non-Small Cell Lung | 190 ± 36 μM | 3.56 ± 1.4 μM | 6.86 ± 0.39 μM |
| IGROV1 | Ovarian | 230 ± 33 μM | 5.64 ± 1.3 μM | 8.08 ± 2.9 μM |
| COLO 205 | Colorectal | 266 ± 57 μM | 16.7 ± 7.2 μM | 2.84 ± 0.64 μM |
| HCT-116 | Colorectal | 281 ± 50 μM | 4.22 ± 2.5 μM | 1.10 ± 0.28 μM |
| OVCAR-3 | Ovarian | 328 ± 128 μM | 5.10 ± 3.0 μM | 1.24 ± 0.30 μM |
| MCF7 | Breast | 335 ± 104 μM | 15.6 ± 6.4 μM | 1.70 ± 0.54 μM |
| HCC-2998 | Colorectal | 381 ± 103 μM | 11.8 ± 4.0 μM | 7.27 ± 2.3 μM |
| MDA-435 | Breast /Melanoma | 401 + 156 μM | 5.81 + 4.0 μM | 12.7 + 5.6 μM |
| HT29 | Colorectal | 443 + 255 μM | 11.9 + 4.1 μM | 6.65 + 1.0 μM |
Data are means +/- SEM from three separate experiments, each performed in triplicate.